---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-24-000017"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T03:04:54.556683+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zymeworks reports FY 2023 net loss of $118.7M; zanidatamab BLA initiated; cash runway into 2027

## Summary
- Revenue $76.0M vs $412.5M in 2022, reflecting non-recurring Jazz upfront; net loss of $118.7M vs net income $124.3M.
- Cash, cash equivalents and marketable securities $456.3M as of Dec 31; with milestone payments, runway into 2H 2027.
- Rolling BLA for zanidatamab in second-line biliary tract cancers started by Jazz; expected completion 1H 2024.
- Jazz initiated Phase 3 confirmatory trial for zanidatamab as first-line BTC; BeiGene expects NMPA BLA filing 2H 2024.
- Targeting two IND submissions in 2024 (ZW191, ZW171); ZW49 Phase 2 deprioritized pending collaboration.

## SEC filing metadata
- accession: 0001937653-24-000017
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000017/0001937653-24-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000017/zyme-20240306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-24-000017
- JSON: https://secwatch.observer/filing/0001937653-24-000017.json
- Plain text: https://secwatch.observer/filing/0001937653-24-000017.txt

## Key facts
- Earnings Releases
  Zymeworks Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000017/0001937653-24-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.